TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01345357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Study: NCT02876536

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: The effect of TENS device will be compared in case and control groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: The effect of TENS device will be compared in case and control groups.
Study: NCT01209702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Administered intravenously (iv) every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Administered intravenously (iv) every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Administered intravenously (iv) every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to tocilizumab administered intravenously every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to tocilizumab administered intravenously every 4 weeks
Study: NCT02121821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder messages
Description: The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
Study: NCT00647959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Tablets, 150mg
Description: 150mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoxa Tablets 150 mg
Description: 150mg, single dose fasting
Study: NCT00528450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Study: NCT03452163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMD-200
Description: the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitor
Description: An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
Study: NCT01976741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) oral solution
Description: Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) oral tablet
Description: Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) 800 mg BID
Description: Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) 800 mg BID
Description: Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) 800 mg BID
Description: Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) 800 mg BID
Description: Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
Study: NCT06170099

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonny supported distal jet
Description: distal jet distalizing appliance is supported on two paramedian screw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bonny supported distal jet
Description: distal jet distalizing appliance is supported on two paramedian screw
Study: NCT03446404

Intervention type: DIAGNOSTIC_TEST
Intervention: Standing Computed Tomography
Description: Provides weight bearing 3D view of knees.
Study: NCT03725618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever 17DD Vaccine
Description: live attenuated vaccine based on the 17DD strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever 17DD Vaccine
Description: live attenuated vaccine based on the 17DD strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever 17DD Vaccine
Description: live attenuated vaccine based on the 17DD strain
Study: NCT01146795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
Study: NCT04413617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 11 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 11 mg
Study: NCT04712630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-incised papila surgical approach without grafting biomaterial
Description: Periodontal reconstructive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-incised papila surgical approach with grafting biomaterial
Description: Periodontal reconstructive surgery
Study: NCT03372681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isoperistaltic Billroth II + Braun anastomosis
Description: Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antiperistaltic Billroth II + Braun anastomosis
Description: Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
Study: NCT02039024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- DTBZ
Description: During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
Study: NCT02023697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Study: NCT00845897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: 200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: 200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
Study: NCT01802138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated T lymphocyte
Description: intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour.
Study: NCT02009280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of anesthesia: Propofol
Description: Maintenance of anesthesia with the propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of anesthesia: Sevoflurane
Description: Maintenance of anesthesia with the sevoflurane
Study: NCT01776216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy diet
Description: During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
Study: NCT02340637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Kids
Description: The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual
Study: NCT03739125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study: NCT00776516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: oral
Study: NCT04685889

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device.
Study: NCT04106076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART123
Description: Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
Study: NCT00887211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
Study: NCT03865381

Intervention type: DEVICE
Group type: OTHER
Intervention: Onduo App
Description: The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
Study: NCT04302909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: focused extracorporeal shock wave therapy
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham focused extracorporeal shock wave therapy
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: night splint
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: night splint
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
Study: NCT00652106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
Description: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
Description: Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.2% ophthalmic solution
Description: Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
Study: NCT03306316

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Prebiotic experimental group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Control
Description: Dextrose Control
Study: NCT04013659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation
Description: After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation
Description: After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
Study: NCT01377337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium bicarbonate
Description: 1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: 1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).
Study: NCT03815266

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computerized Mirror Therapy (CMT)
Description: Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tolerance Assessment Questionnaire
Description: The Tolerance Assessment Questionnaire will be completed at the end of each session.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ashworth's scale
Description: Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Frenchay arm test
Description: Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abilhand questionnaire
Description: Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer test
Description: Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scaling (GAS)
Description: Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after.
Study: NCT01957046

Intervention type: DRUG
Group type: OTHER
Intervention: Laxative